Hrubá marže společnosti Adma Biologics Inc

Jaká je hodnota metriky Hrubá marže společnosti Adma Biologics Inc?

Hodnota metriky Hrubá marže společnosti Adma Biologics Inc je 34.44%

Jaká je definice metriky Hrubá marže?



Hrubá marže (Gross margin) je rozdíl mezi příjmy a náklady na prodané zboží dělený příjmy a vyjádřený v procentech.

Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.

Hrubá marže společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Adma Biologics Inc

Čemu se věnuje společnost Adma Biologics Inc?

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

Firmy s metrikou hrubá marže podobnou společnosti Adma Biologics Inc